CT 0181
Alternative Names: CT-0181; CT0181 humanised anti GPC3 autogenous T Cell injection - CARSgenLatest Information Update: 25 Mar 2022
At a glance
- Originator CARsgen
- Developer CARsgen; Peking University
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 23 Mar 2022 Pharmacodynamics data from preclinical studies in Liver cancer released by CARSgen
- 22 Jul 2021 Preclinical trials in Liver cancer in China (Parenteral)
- 22 Jul 2021 CARsgen plans a phase I trial for Liver cancer (Late stage disease, Second-line therapy or greater) in China (Infusion) in August 2021 (NCT04973098)